Evidence map›Paper›PMID 26699393›Full record

ArticleCirculation. Heart failure2016

Prediction of All-Cause Mortality Based on the Direct Measurement of Intrathoracic Impedance.

Michael R Zile, Vinod Sharma, James W Johnson, Eduardo N Warman, Catalin F Baicu, Tom D Bennett

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Circulation. Heart failure, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Trial
  2. Review
  3. Remote monitoring data from cardiac implantable electronic devices predicts all-cause mortality.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2022
    Article
  4. Article
  5. Article
  6. Article
  7. Observational
  8. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Michael R ZileFrom the Division of Cardiology, Department of Medicine, Medical University of South Carolina and RHJ Department of Veterans Affairs Medical Center, Charleston (M.R.Z., C.F.B.); and Medtronic, Plc., Minneapolis, MN (V.S., J.W.J., E.N.W., T.D.B.). zilem@musc.edu.
Vinod SharmaFrom the Division of Cardiology, Department of Medicine, Medical University of South Carolina and RHJ Department of Veterans Affairs Medical Center, Charleston (M.R.Z., C.F.B.); and Medtronic, Plc., Minneapolis, MN (V.S., J.W.J., E.N.W., T.D.B.).
James W JohnsonFrom the Division of Cardiology, Department of Medicine, Medical University of South Carolina and RHJ Department of Veterans Affairs Medical Center, Charleston (M.R.Z., C.F.B.); and Medtronic, Plc., Minneapolis, MN (V.S., J.W.J., E.N.W., T.D.B.).
Eduardo N WarmanFrom the Division of Cardiology, Department of Medicine, Medical University of South Carolina and RHJ Department of Veterans Affairs Medical Center, Charleston (M.R.Z., C.F.B.); and Medtronic, Plc., Minneapolis, MN (V.S., J.W.J., E.N.W., T.D.B.).
Catalin F BaicuFrom the Division of Cardiology, Department of Medicine, Medical University of South Carolina and RHJ Department of Veterans Affairs Medical Center, Charleston (M.R.Z., C.F.B.); and Medtronic, Plc., Minneapolis, MN (V.S., J.W.J., E.N.W., T.D.B.).
Tom D BennettFrom the Division of Cardiology, Department of Medicine, Medical University of South Carolina and RHJ Department of Veterans Affairs Medical Center, Charleston (M.R.Z., C.F.B.); and Medtronic, Plc., Minneapolis, MN (V.S., J.W.J., E.N.W., T.D.B.).

Funding

Extracellular Matrix in Hypertensive Heart Disease & Transition to Heart FailureR01HL123478 · NHLBI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI ZILE, MICHAEL R · 2015 to 2018
$1.5M
Extracellular Matrix in Hypertensive Heart Disease & Transition to Heart FailureR56HL123478 · NHLBI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI ZILE, MICHAEL R · 2014 to 2014
$387k
Connexin Distribution in Physiological Versus Pathological Cardiac HypertrophyI01BX000487 · VA · RALPH H JOHNSON VA MEDICAL CENTER · PI ZILE, MICHAEL R · 2009 to 2013
–
AGE/RAGE Interaction in Patients with Pressure Overload-Induced Heart FailureI01CX000415 · VA · RALPH H JOHNSON VA MEDICAL CENTER · PI ZILE, MICHAEL R · 2011 to 2014
–
BLRD VA I01 BX000487CSRD VA I01 CX000415NHLBI NIH HHS R01 HL123478NHLBI NIH HHS R56 HL123478NHLBI NIH HHS R56HL123478
6 · The paper itself

Abstract

backgroundIntrathoracic impedance-derived OptiVol fluid index calculated using implanted devices has been shown to predict mortality; direct measurements of impedance have not been examined. We hypothesized that baseline measured impedance predicts all-cause mortality; changes in measured impedance result in a change in the predicted mortality; and the prognostic value of measured impedance is additive to the calculated OptiVol fluid index. METHODS AND

resultsA retrospective analysis of 146,238 patients within the Medtronic CareLink database with implanted devices was performed. Baseline measured impedance was determined using daily values averaged from month 6 to 9 after implant and were used to divide patients into tertiles: group L = low impedance, ≤ 65 ohms; group M = medium impedance, 66 to 72 ohms; group H = high impedance, ≥ 73 ohms. Change in measured impedance was determined from values averaged from month 9 to 12 post implant compared with the 6- to 9-month values. OptiVol fluid index was calculated using published methods. All-cause mortality was assessed beginning 9 months post implant; changes in mortality was assessed beginning 12 months post implant. Baseline measured impedance predicted all-cause mortality; 5-year mortality for group L was 41%, M was 29%, and H was 25%, P < 0.001 among all groups. Changes in measured impedance resulted in a change in the predicted mortality; the prognostic value of measured impedance was additive to the OptiVol fluid index.

conclusionsDirect measurements of intrathoracic impedance using an implanted device can be used to stratify patients at varying mortality risk.

Indexed as

Cardiography, ImpedanceTelemetryAgedAged, 80 and overCardiac Resynchronization TherapyCardiac Resynchronization Therapy DevicesCause of DeathDatabases, FactualDefibrillators, ImplantableElectric CountershockFemaleHeart FailureHumansKaplan-Meier EstimateMaleMiddle Agedall-cause mortalityheart failureimpedancerisk

Identifiers

PMID26699393
PMCPMC4692195

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.